M-Marsel Mesulam Selected Research

Primary Progressive Aphasia

11/2020	APOE is a correlate of phenotypic heterogeneity in Alzheimer disease in a national cohort.
1/2020	Differential neurocognitive network perturbation in amnestic and aphasic Alzheimer disease.
1/2019	Cortical cholinergic denervation in primary progressive aphasia with Alzheimer pathology.
1/2018	Combined Pathologies in FTLD-TDP Types A and C.
5/2017	Cerebrospinal fluid markers detect Alzheimer's disease in nonamnestic dementia.
3/2016	Is in vivo amyloid distribution asymmetric in primary progressive aphasia?
2/2016	Asymmetric pathology in primary progressive aphasia with progranulin mutations and TDP inclusions.
4/2014	Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia.
7/2013	Primary progressive aphasia and the language network: the 2013 H. Houston Merritt Lecture.
12/2005	Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M-Marsel Mesulam Research Topics

Disease

11	Dementia (Dementias) 10/2021 - 05/2004
11	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 12/2005
11	Primary Progressive Aphasia 11/2020 - 11/2004
5	Atrophy 01/2021 - 05/2012
5	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 01/2018 - 10/2009
4	Frontotemporal Dementia (Semantic Dementia) 01/2018 - 04/2013
3	Cognitive Dysfunction 01/2022 - 01/2018
3	Tauopathies 04/2014 - 10/2009
3	Proteostasis Deficiencies 04/2014 - 10/2009
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2019 - 12/2005
2	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 05/2017 - 04/2014
2	Aphasia (Dysphasia) 11/2016 - 09/2016
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 04/2013 - 12/2005
1	Gliosis 01/2019
1	Disease Progression 01/2018
1	Broca Aphasia (Expressive Aphasia) 04/2014
1	Motor Neuron Disease (Primary Lateral Sclerosis) 04/2013
1	Prion Diseases (Transmissible Spongiform Encephalopathies) 12/2005
1	Pick Disease of the Brain (Pick's Disease) 10/2003

Drug/Important Bio-Agent (IBA)

7	Amyloid (Amyloid Fibrils)IBA 01/2022 - 04/2014
7	DNA-Binding Proteins (DNA Binding Protein)IBA 01/2021 - 10/2009
4	Apolipoproteins E (ApoE)IBA 01/2021 - 07/2013
4	Biological ProductsIBA 01/2018 - 05/2012
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 09/2016
3	Cholinergic Agents (Cholinergics)IBA 01/2019 - 12/2013
2	ProgranulinsIBA 01/2018 - 02/2016
2	Proteins (Proteins, Gene)FDA Link 01/2018 - 06/2014
1	HLA-DR Antigens (HLA-DR)IBA 01/2021
1	thioflavin TIBA 01/2021
1	Inflammation MediatorsIBA 01/2019
1	Pharmaceutical PreparationsIBA 01/2018
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2018
1	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2018
1	florbetapirIBA 03/2016
1	UbiquitinIBA 04/2013
1	Codon (Codons)IBA 12/2005
1	Prion ProteinsIBA 12/2005
1	Bromocriptine (Parlodel)FDA LinkGeneric 11/2004
1	AntibodiesIBA 05/2004
1	SteroidsIBA 05/2004
1	Protein Isoforms (Isoforms)IBA 10/2003

Therapy/Procedure

2	Therapeutics 01/2019 - 01/2018
1	Activities of Daily Living (ADL) 10/2021
1	Denervation 01/2019
1	Drug Therapy (Chemotherapy) 01/2018
1	Language Therapy (Language Training) 11/2016